Clinical trial
EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) Study Program
NCT03363464 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) Study Program
- Lead sponsor
- Boehringer Ingelheim
- Phase
- Observational
- Overall status
- Completed
- Start date
- October 16, 2017
- Completion date
- July 9, 2026
- Enrollment
- Not reported
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.